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INTRODUCTION AND AIMS: Increased activity of the intrarenal renin-angiotensin-
aldosterone system (RAAS) is the main pathogenic mechanism for the development of early
hypertension in patients with autosomal dominant polycystic kidney disease (ADPKD).
Moreover, intrarenal RAAS is an important component for renal potassium handling and
maintaining potassium balance. The recent HALT-PKD trial for ADPKD showed that epi-
sodes of hyperkalemia were infrequently observed despite dual blocking in RAAS. The aims
of this study were to investigate whether high intrarenal RAAS activity affects serum potas-
sium levels and whether it acts as a prognostic marker in patients with ADPKD.
METHODS: This prospective longitudinal study was conducted with 1788 subjects
from the KoreaN cohort study for Outcome in patients With Chronic Kidney Disease
(KNOW-CKD). The baseline urinary angiotensinogen (AGT) level was measured using
a commercially available enzyme-linked immunosorbent assay kit. Propensity score
matching (PSM) analysis was performed to compare potassium handling between the
ADPKD and non-PKD groups. The primary outcome of this study was the composite
of all-cause mortality and renal function decline.
RESULTS: Patients’ mean age was 54.0 6 12.2 years, and 690 (38.6%) were women.
The average estimated glomerular filtration rate was 50.1 6 29.9 mL/min/1.73 m2. The
risk of hyperkalemia was significantly lower in ADPKD than in other causes of chronic
kidney disease after adjusting the covariables. In multivariable linear regression analy-
sis, the urinary AGT/creatinine (Cr) ratio was negatively correlated with the serum
potassium level (b¼ -0.058, P¼ 0.017) and positively associated with the transtubular
potassium gradient (TTKG, b¼ 0.087, P¼ 0.001). After PSM, patients with ADPKD
had significantly lower serum potassium levels (P< 0.001) with oppositely elevated
TTKGs (P¼ 0.024). Additionally, the urinary AGT/Cr ratio was significantly higher in
ADPKD than in non-PKD (P¼ 0.003). These results were much prominent in the com-
parison between ADPKD and diabetic nephropathy. In 293 patients with ADPKD, the
urinary AGT/Cr ratio was a significant risk factor of the composite outcome (hazard
ratio, 1.33; 95% confidence interval, 1.10-1.62; P¼ 0.004).
CONCLUSIONS: Increasing activity of intrarenal RAAS represented by a high urinary
AGT level is associated with high tubular potassium excretion and a low serum potas-
sium level, and is a prognostic marker in patients with ADPKD. The present study sug-
gests that a higher degree of RAAS blockade may be needed to inhibit intrarenal RAAS
activity in patients with ADPKD.
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INTRODUCTION AND AIMS: Hyperuricemia is an independent risk factor for
chronic kidney disease (CKD) and contributes to renal fibrosis. Excessive uric acid in
the body leads to hyperuricemic nephropathy (HN), which is characterized by glomer-
ular hypertension, arteriolosclerosis, and tubulointerstitial fibrosis. Fatty acid binding
protein-4 (FABP4) is a mediator of inflammatory response and FABP4 activation is
involved in chronic renal injury. However, whether FABP4 mediates the development
of HN remains unknown. Here, we aimed to investigate the role of FABP4 in the devel-
opment of HN and the mechanisms involved.
METHODS: Eighteen male mice were randomly assigned to three groups of six mice:
sham group, HN group, and HNþBMS group (HN mice treated with a highly selective
FABP4 inhibitor BMS309403, 40 mg/kg/d). The HN mouse model was established by
oral administration of a mixture of potassium oxonate (2.4 g/kg) and adenine (0.16 g/
kg) daily consistently for 3 weeks. Urinary albumin, urinary uric acid excretion, serum
uric acid, creatinine, and BUN were determined. Renal histological injury was meas-
ured by PAS and Masson’s trichrome staining. Renal tissues of the mice were analyzed
by immunohistochemical, immunofluorescence, western blot and real-time PCR assay
for the expression of proteins and genes.
RESULTS: In HN mouse model, increased level of FABP4, glomerular sclerosis and
renal interstitial fibrosis were evident, accompanied by renal dysfunction and increased
urinary albumin excretion. Administration of BMS309403 prevented renal dysfunc-
tion, reduced 24h urine albumin and alleviated renal histopathologic changes.
BMS309403 treatment also inhibited the activation of TGF-b1 signaling pathways and
expression of multiple profibrogenic cytokines in the kidneys of mice induced by
hyperuricemia.
CONCLUSIONS: These findings suggested that FABP4 was an important contributor
to hyperuricemic nephropathy by the activation of TGF-b1 signaling and pharmaco-
logical inhibition of FABP4 might be a promising therapeutic strategy for hyperurice-
mic nephropathy.
FP042 ATMIN MODULATES PKHD1 EXPRESSION AND THROUGH
ALTERED NON-CANONICAL WNT/PLANAR CELL POLARITY
(PCP) SIGNALLING MEDIATES ARPKD SEVERITY
Paraskevi Goggolidou3,2, Taylor Richards3, Kavindiya Modarage3,
Charlotte Dean1, Jill Norman2, Patricia Wilson2
1National Heart and Lung Institute, Imperial College London, London, United Kingdom,
2Centre for Nephrology, University College London, London, United Kingdom and
3Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton,
United Kingdom
INTRODUCTION AND AIMS: ARPKD is a genetic disorder with an incidence of
~1:20,000 that can lead to perinatal mortality. In the ~60% of ARPKD patients who
survive the neonatal period, there is a range of disease severity, however, little is known
about the genetic mechanisms that regulate ARPKD. ARPKD is caused by mutations in
PKHD1 which encodes the large membrane protein, fibrocystin, required for normal
branching morphogenesis of the ureteric bud during embryonic renal development.
The range of disease severity observed in ARPKD suggests that besides PKHD1 that
when mutated causes ARPKD, other genes might also play a role in ARPKD, acting as
modifiers of disease severity.
METHODS: Quantitative Real-time PCR and immunohistochemistry in age-matched
normal and ARPKD human kidneys were employed in addition to the AtminGpg6
mouse and siRNA-mediated knockdowns in mIMCD3 cells, to investigate the relation-
ship between fibrocystin and non-canonical Wnt signalling.
RESULTS: In normal human kidneys ATMIN, VANGL2, Inversin and b-catenin were
expressed in ureteric bud-derived collecting tubules, whereas in age-matched ARPKD
tissue, strong ATMIN and VANGL2 and moderate Inversin and b-catenin expression
were observed in cyst-lining epithelia. Significant increases in ATMIN, WNT5A,
VANGL2 and SCRIBBLE mRNA expression were seen in human ARPKD versus normal
kidneys; no considerable differences were seen in DAAM2 or NPHP2. A striking
increase in E-cadherin was also detected in ARPKD kidneys. Investigations of the
AtminGpg6 mouse showed that it is a novel mouse model of ARPKD. Further, loss of
Atmin affected the transcriptional regulation of Pkhd1 and restored cellular prolifera-
tion to normal levels.
CONCLUSIONS: This work suggests the novel role of non-canonical Wnt signalling in
ARPKD and proposes ATMIN as a modifier of ARPKD that could in the long term be
used as a biomarker of ARPKD severity and progression.
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